Alpha-1 Foundation   Report issue

Foundation Phase 1 Phase 2
Founded: Coral Gables FL United States (1995)

Organization Overview

First Clinical Trial
2001
NCT00067756
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

acetylsalicylic acid (aspirin) (1 trial)

sodium phenylbutyrate (buphenyl) (1 trial)

Drugs in Phase 1 Trials (1)

raav1-cb-haat (1 trial)

Drugs in Other Trials (1)

raav2-cb-haat gene (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

alpha 1-Antitrypsin Deficiency (Phase 2)

Emphysema (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Pulmonary Emphysema (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4